First short refresh on tolerance

Size: px
Start display at page:

Download "First short refresh on tolerance"

Transcription

1 First short refresh on tolerance

2

3

4

5

6 Su et al. Immunity 2013 Number of Ag specific cells A Tet + cells (per 10 6 CD4) 100 No evidence for clonal deletion? Antigen Specificity: HIV CMV HSV-naive HSV-exposed FLU-HA FLU-PB1 FLU-PA tetanus Fib gp100 PPins Frequencies of tetramer-tagged cells per million CD4 T cells. Each symbol represents an antigen-specific population from one individual. Fib (fibrogen), gp100, PPins (preproinsulin): self antigens.

7 Polly Matzinger & Michel Oldstone Anderson et al J Immunol 2001 Graft male tissue onto female mouse lacking an immune system o graft is rejected when immune system reconstitutes o graft is accepted when female receives a male thymus Ohashi et al Cell 1991, Oldstone et al Cell 1991: Induction of diabetes by viral infection of transgenic mice expressing LCMV protein in pancreas o mice are normal, no evidence for tolerance o infect mice with LCMV: virus is rejected but later mice develop diabetes

8 Testing Time-, Ignorance-, and Danger-Based Models of Tolerance Colin C. Anderson, 1 * Joseph M. Carroll, Stefania Gallucci,* John P. Ridge,* Allen W. Cheever, and Polly Matzinger* In this study, we present data showing that tolerance to Ags in the periphery is not determined by the time at which the Ag appears, or by special properties of tissues in newborn mice or newly developing immune systems. We placed male grafts onto immunoincompetent female mice, allowed the grafts to heal for up to 5 mo, and then repopulated the recipients with fetal liver stem cells. We found that the newly arising T cells were neither tolerant nor ignorant of the grafts, but promptly rejected them, though they did not reject female grafts, nor show any signs of autoimmunity. We also found that the H-Y Ag was continuously cross-presented on host APCs, that this presentation was immunogenic, not tolerogenic, and that it depended on the continuous presence of the graft. In searching for the stimulus that might activate the host APCs, we analyzed mrna expression with a highly sensitive real-time quantitative PCR assay. By using two different housekeeping molecules for comparison, we analyzed the message levels for several stress and/or inflammatory molecules in the healed grafts. We found that the long-healed grafts were not equivalent to normal skin because the healed grafts expressed lower levels of GAPDH. Altogether, these data suggest that acceptance vs rejection of peripheral tissues is not attributable to ignorance, timing-based tolerance, or special circulation properties of naive T cells in neonatal tissues. It is more likely attributable to an aspect of the context of Ag presentation that remains to be identified. The Journal of Immunology, 2001, 166: ARTICLES 2001 Nature Publishing Group Immunity or tolerance: Opposite outcomes of microchimerism from skin grafts COLIN C. ANDERSON & POLLY MATZINGER Ghost Lab, Section on T-cell Tolerance and Memory, Laboratory of Cellular and Molecular Immunology, NIAID/NIH Building 4 Room 111, 9000 Rockville Pike, Bethesda, Maryland , USA Correspondence should be addressed to C.C.A.; canderson@niaid.nih.gov

9 Testing Time-, Ignorance-, and Danger-Based Models of Tolerance FIGURE 1. Well-healed skin grafts induce immunity. A, B6 nude female mice (n 6) were given a B6 nude male skin graft and 9 wk later were given a neonatal B6 female thymus graft. B, B6 nude female recipients received a B10-RAG male skin graft and, 9 wk later, a neonatal male (dashed line; n 4) or female (solid line; n 4) B10-RAG thymus. C, B10-RAG female recipients (n 4) received two skin grafts, a B10-RAG female (dashed line) and male skin graft (solid line). Eleven weeks later, they were reconstituted with day-15 B6 female fetal liver cells. D, Thymectomized B10-RAG female recipients received a B10-RAG male skin graft and 7 wk later were reconstituted with day-15 B6 female fetal liver cells and thymus graft (solid line; n 6). Controls (dashed line) were similarly treated except they received a male fetal thymus graft (n 1) or a female skin graft (n 2).

10 A simple mathematical model

11 A simple mathematical model S number of self epitopes evoking tolerance (10 5 ) [Burroughs.i04] R0 potential repertoire (before tolerance) (huge: ) R functional repertoire after tolerance (> 10 8 ) [Arstila.s99] p recognition probability (precursor freq ) [Blattman.jem02]! Size of functional repertoire: R = R 0 (1 p) S Probability of responding to foreign epitope: P i =1 (1 p) R Taking the derivative of Pi to p gives the optimum p = 1 S 10 5

12 A simple mathematical model Pi 1 Too specific Too much deletion 0.8 1/S SPECIFIC DEGENERATE Cross-reactivity (log(p))

13 Lymphocytes are specific AND recognize many peptides peptides 5 > 10 peptides Repertoire: 8 10 clones Because there are many more peptides ( ) than clones we need sufficient cross-reactivity (Mason.it98).! But each peptide is recognized by very few clones: p 10 5

14 none of the clonotypes recognizing foreign epitope or te we f = define 1 the a new newparameter l to induce tolerance. Incomplete model should f for the Otherwise tolerance be fraction identical of self to the epitop he new model should be identical the the clone previous will beone. heldfor a zed, l. [4] but we that let none be the of fraction the clonotypes of clonotypes recognizing recognizing the foreign is recognized, but that none of the clonotypes recog f S number of self epitopes evoking tolerance (0 < f <= 1) R0 potential repertoire, R functional repertoire, p precursor freq. )S self epitopes that fail to induce tolerance. Other itopes that fail to induce tolerance. Otherwise the clone will Borghans Following p) (1 f)s et. Borghans al. [4] we let et al. be[4] thewe fraction let of clonotypes (4) rec Fraction of clones recognizing at least one ignored self epitope: e, i.e., mulated with a foreign =1 (1 p) (1 f)s epitope is the probability that =1 (1 p) =1 (1 f)s.(1 p) spond (with chance p) and is potentially (1 f)s. auto-reactive rant Size when of functional stimulated repertoire: with a foreign epitope is the probabil Probability to remain tolerant: etoire R R= will R 0 (1respond p) fs (with. chance p) and is potentially (5) auto- the p ) probability R where that R = Rthe system remains tolerant and 0 (1 p) fs. emain P tolerant minus the chance to not respond at all: t = (1 p ) R where R = R 0 (1 p) fs. response is the probability that the system remains toler (1 he chance p) R, to remain tolerant minus the chance to not (6) respond Probability of a successful immune response: be the fraction mains tolerant when stimulated with a foreign epito ional repertoire R will respond (with chance p) and ul immune response is the probability that the sys, which is the chance to remain tolerant minus the cha o study P s = how P t incomplete (1 p) R, tolerance a ects the results we

15 MHC diversity within an individual p probability of positive selection n probability of negative selection Note p > n M number of MHC molecules per host Clones should not be negatively selected on any MHC but should be positively selected by at least one MHC: R = R 0 (1 n) M (1 p) M In mice about 3% of the thymocytes survive and about half of the positively selected cells become negatively selected [Van Meerwijk et al., Merkenschlager et al., J Exp Med 1997]

16 R = R 0 (1 n) M (1 p) M 0.3 R/R MHC diversity (log M) 3 4 Parameters p=0.01 and n=p/2=0.005 [Borghans Eur J Imm 2003]

17 A simulation model: Borghans, Int. Immunol bacterial peptides viral peptides... toxin peptides self peptides Repertoire Set of peptides for each antigen group. Clones will recognize peptides from all sets with probability p.

18 Play an immune system game 1. Make a pathogen by drawing e epitopes from its set 2. Determine phenotype of all clones responding 3. If all naive: switch them to memory of corresponding mode 4. If memory available: switch all to that mode determine succes 5. Goto 1.

19 A simple example Clone numbers: Ro Initial types: Antigen 1, type 7: Zero score Antigen 2, type 5: Zero score Antigen 3, type 5: Positive score Antigen 4, type 9: Negative score

20 10e3 epitopes per set, 10e6 clones Fraction immune responses response positive negative autoimmunity Lymphocyte cross reactivity (p)

21 Fig. 3. The performance of a diverse immune system. The fractions of different immune responses have been plotted for different degrees of cross-reactivity (p), after challenge with 10 3 different pathogens. The thick curve denotes the fraction of challenges that induce any immune response at all. The fraction of challenges in which pre-existing effector/memory clones induce the correct type of immune response is denoted by the thin curve. The fraction of challenges in which pre-existing effector/memory clones induce an inappropriate immune response is denoted by the dashed curve. The fraction of challenges leading to autoimmunity, caused by ignorant self-speci c clones that are triggered by foreign antigens, is denoted by the dash-dotted curve. This repertoire is most functional at a cross-reactivity of p ~ 10 ±6, because the chance of immunity is then close to 1, and the net contribution of pre-existing effector/memory cells is high. There are e = 6 different epitopes per pathogen, pathogens come from m ± 1 = 8 different groups, each consisting of N = 10 3 different epitopes, a fraction f = 0.8 of all S = 10 4 self epitopes induces tolerance and there are R 0 = 10 6 clonotypes.

First short refresh on tolerance

First short refresh on tolerance First short refresh on tolerance Death by neglect What is the diversity of the T cell repertoire? Parham cites estimate from Arstila [Science, 1999]: 2x10 6 Nowadays next generation sequencing (NGS):

More information

Adaptive Immunity: Specific Defenses of the Host

Adaptive Immunity: Specific Defenses of the Host PowerPoint Lecture Presentations prepared by Bradley W. Christian, McLennan Community College C H A P T E R 17 Adaptive Immunity: Specific Defenses of the Host The Adaptive Immune System Adaptive immunity:

More information

Mixed chimerism and split tolerance: Mechanisms and clinical correlations

Mixed chimerism and split tolerance: Mechanisms and clinical correlations Chimerism ISSN: 1938-1956 (Print) 1938-1964 (Online) Journal homepage: http://www.tandfonline.com/loi/kchm20 Mixed chimerism and split tolerance: Mechanisms and clinical correlations David P. Al-Adra &

More information

Chapter 14. Second symmetry

Chapter 14. Second symmetry Chapter 14. Second symmetry Tyger Tyger, burning bright In the forests of the night What immortal hand or eye Could frame thy fearful symmetry? -William Blake Songs of Experience (1794) A good general

More information

Interplay of Cells involved in Therapeutic Agent Immunogenicity. Robert G. Hamilton, Ph.D., D.ABMLI Professor of Medicine and Pathology

Interplay of Cells involved in Therapeutic Agent Immunogenicity. Robert G. Hamilton, Ph.D., D.ABMLI Professor of Medicine and Pathology Interplay of Cells involved in Therapeutic Agent Immunogenicity Robert G. Hamilton, Ph.D., D.ABMLI Professor of Medicine and Pathology Disclosure The author works with Amicus on an immunogenicity project

More information

Brief Det~nitive Report

Brief Det~nitive Report Brief Det~nitive Report THYMIC RECONSTITUTION OF NUDE F MICE WITH ONE OR BOTH PARENTAL THYMUS GRAFTS* BY ROLF M. ZINKERNAGEL, A. ALTHAGE, AND G. CALLAHAN From the Departments of Immunopathology and of

More information

FDA Perspective on the Preclinical Development of Cancer Vaccines

FDA Perspective on the Preclinical Development of Cancer Vaccines FDA Perspective on the Preclinical Development of Cancer Vaccines Richard D. McFarland Ph.D., M.D. Medical Officer CBER/OCTGT/DCEPT mcfarlandr@cber.fda.gov Cancer Vaccine Clinical Trials Workshop Alexandria,

More information

Supplementary Figure 1. Characterization of the POP2 transcriptional and post-transcriptional regulatory elements. (A) POP2 nucleotide sequence

Supplementary Figure 1. Characterization of the POP2 transcriptional and post-transcriptional regulatory elements. (A) POP2 nucleotide sequence 1 5 6 7 8 9 10 11 1 1 1 Supplementary Figure 1. Characterization of the POP transcriptional and post-transcriptional regulatory elements. (A) POP nucleotide sequence depicting the consensus sequence for

More information

Chapter 3 Antigen bias in T cell cross priming

Chapter 3 Antigen bias in T cell cross priming Chapter 3 Antigen bias in T cell cross priming Science 2004 May 28;304(5675):1314 7 Antigen Bias in T Cell Cross-Priming Monika C. Wolkers, Nathalie Brouwenstijn,* Arnold H. Bakker,* Mireille Toebes,

More information

Immunogenicity of Stem Cells in Therapeutic Applications. MDPB-Registry meeting nov 25th Stem cell immunogenicity in therapeutic applications

Immunogenicity of Stem Cells in Therapeutic Applications. MDPB-Registry meeting nov 25th Stem cell immunogenicity in therapeutic applications Immunogenicity of Stem Cells in Therapeutic Applications MDPB-Registry meeting nov 25th 2016 Stem cell immunogenicity in therapeutic applications Has it been underestimated? Transplantation of any type

More information

Therapeutic Proteins BIT 230

Therapeutic Proteins BIT 230 Therapeutic Proteins BIT 230 CLOTTING Haemophilia Benefix Blood Products ANTICOAGULANT THROMBOLYTIC AGENTS tissue plasminogen activator streptokinase Coagulation pathway Factor VIII (Haemophilia A) Factor

More information

OpenStax-CNX module: m Antibodies * OpenStax. Abstract

OpenStax-CNX module: m Antibodies * OpenStax. Abstract OpenStax-CNX module: m44823 1 Antibodies * OpenStax This work is produced by OpenStax-CNX and licensed under the Creative Commons Attribution License 3.0 By the end of this section, you will be able to:

More information

Supplementary figures

Supplementary figures Mucida et al. Supplementary material Supplementary figures Supplementary Figure 1. Oral administration of OVA suppresses Th2 differentiation, Germinal Center (GC) formation and immunoglobulin class switching

More information

Examination in Immunotechnology, 30 May 2011, 8-13

Examination in Immunotechnology, 30 May 2011, 8-13 Examination in Immunotechnology, 30 May 2011, 8-13 1 Each question can give 5p, with a total of 10 questions (i.e. 50 points in total). 2 Write name and personal number on ALL pages (including the cover).

More information

Immunological Applications. Chapter 8: Background

Immunological Applications. Chapter 8: Background Immunological Applications Chapter 8: Background The Immune System Types of Immunity Innate The natural immunity present at birth Acquired A specific response to foreign substances. Some cells remember

More information

Immunology 101: Implications for Medical Device Failure. Joshua B. Slee, PhD Assistant Professor of Biology

Immunology 101: Implications for Medical Device Failure. Joshua B. Slee, PhD Assistant Professor of Biology Immunology 101: Implications for Medical Device Failure Joshua B. Slee, PhD Assistant Professor of Biology Learning Goals Understand innate and adaptive immunity Explain how innate and adaptive immunity

More information

Jedi cells patrol the mouse

Jedi cells patrol the mouse Jedi cells patrol the mouse Technical Journal Club Josephin Wagner 19.01.2016 12 VOL.13 NO.1 JANUARY 2016 NATURE METHODS Introduction JEDI= Just EGFP Death Inducing t- cells Specific CD-8 T cells All EGFP

More information

1 Name. 1. (3 pts) What is apoptosis and how does it differ from necrosis? Which is more likely to trigger inflammation?

1 Name. 1. (3 pts) What is apoptosis and how does it differ from necrosis? Which is more likely to trigger inflammation? 1 Name MCB 150 Midterm Eam #1 (100 points total) Please write your full name on each page of the eam!! The eam consists of 17 questions (6 pages). Each has a different point count as indicated. Please

More information

IEDB Overview. Bjoern Peters, Ph.D. Associate Professor IEDB Co-Principal Investigator

IEDB Overview. Bjoern Peters, Ph.D. Associate Professor IEDB Co-Principal Investigator IEDB Overview Bjoern Peters, Ph.D. Associate Professor IEDB Co-Principal Investigator 1 The Immune Epitope Database Free online resource of experimentally-derived epitope information T T B Allergens APC

More information

ANTIBODIES. Agents of Immunity

ANTIBODIES. Agents of Immunity ANTIBODIES Agents of Immunity - Antibodies are: The Organization What are they? Protective agents of the immune system Neutralize foreign agents called antigens Essential part of the Adaptive Immune System

More information

Finding Data in the IEDB 3.0. Kerrie Vaughan, PhD - Sr. Biocurator/Meta-Analysis Nima Salimi, MS - Sr. Biocurator/Curation Mgr

Finding Data in the IEDB 3.0. Kerrie Vaughan, PhD - Sr. Biocurator/Meta-Analysis Nima Salimi, MS - Sr. Biocurator/Curation Mgr Finding Data in the IEDB 3.0 Kerrie Vaughan, PhD - Sr. Biocurator/Meta-Analysis Nima Salimi, MS - Sr. Biocurator/Curation Mgr 1 Finding Data in the IEDB 3.0 IEDB Overview Content and Organization IEDB

More information

Recombination Lecture, Dr. Aguilera 2/17/2014

Recombination Lecture, Dr. Aguilera 2/17/2014 Lymphocytes and Antigen Receptors Thymus T-Cells Lymph nodes Spleen } T+B-cells Paper Presentation: Bone Marrow Stem cells and B-cells Nat. Rev. Immunol. STEM CELL CLP Committed Lymphocyte Precursor T-cells

More information

Structure-Guided Deimmunization CMPS 3210

Structure-Guided Deimmunization CMPS 3210 Structure-Guided Deimmunization CMPS 3210 Why Deimmunization? Protein, or biologic therapies are proving to be useful, but can be much more immunogenic than small molecules. Like a drug compound, a biologic

More information

AUTOIMMUNE HEPATITIS EXPERIMENTAL MODEL BASED ON. Sainte-Justine University Hospital, Montreal (Quebec), H3T 1C5, Canada; 3 Departments

AUTOIMMUNE HEPATITIS EXPERIMENTAL MODEL BASED ON. Sainte-Justine University Hospital, Montreal (Quebec), H3T 1C5, Canada; 3 Departments 1 2 AUTOIMMUNE HEPATITIS EXPERIMENTAL MODEL BASED ON ADENOVIRAL INFECTIONS 3 4 Authors: Pascal Lapierre 1, Kathie Béland 2 and Fernando Alvarez 2,3,4 5 6 7 Affiliations: 1 Immunovirology Laboratory, INRS-Institut

More information

isolated from ctr and pictreated mice. Activation of effector CD4 +

isolated from ctr and pictreated mice. Activation of effector CD4 + Supplementary Figure 1 Bystander inflammation conditioned T reg cells have normal functional suppressive activity and ex vivo phenotype. WT Balb/c mice were treated with polyi:c (pic) or PBS (ctr) via

More information

HSV-2 therapeutic vaccine program. Subunit vaccine candidates

HSV-2 therapeutic vaccine program. Subunit vaccine candidates HSV-2 therapeutic vaccine program Subunit vaccine candidates Our HSV-2 vaccine program Therapeutic subunit vaccine T-cell-based Aim: Best-in-class antigens by engineering Excellent standing (Sept 2017):

More information

Receptor Revision Diminishes the Autoreactive B Cell Response after Antigen. PNA Tet. Day 8. Day 16

Receptor Revision Diminishes the Autoreactive B Cell Response after Antigen. PNA Tet. Day 8. Day 16 Receptor Revision Diminishes the Autoreactive Cell Response after Antigen Activation Ying-Hua Wang and etty Diamond Supplemental data: PNA Tet 5 8 11 16 Supplemental Figure 1: Kinetic analysis of tetramer-binding

More information

Course Agenda. Day One

Course Agenda. Day One Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an

More information

HOST DEFENSE SMALL GROUP PROBLEM SOLVING SESSION CLINICAL IMMUNOLOGIC ASSAYS-II

HOST DEFENSE SMALL GROUP PROBLEM SOLVING SESSION CLINICAL IMMUNOLOGIC ASSAYS-II HOST DEFENSE SMALL GROUP PROBLEM SOLVING SESSION CLINICAL IMMUNOLOGIC ASSAYS-II Monday, March 24, 2008 2:00 PM 4:00 PM Small Group Classrooms LEARNING GOAL Understanding in vitro assessment of immunologic

More information

Supporting Information

Supporting Information (xe number cells) LSK (% gated) Supporting Information Youm et al../pnas. SI Materials and Methods Quantification of sjtrecs. CD + T subsets were isolated from splenocytes using mouse CD + T cells positive

More information

CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION

CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION The specificity of humoral immune responses relies on the huge DIVERSITY of antigen combining sites present in antibodies, diversity which

More information

T cell epitopes in HSCT

T cell epitopes in HSCT T cell epitopes in HSCT Katharina Fleischhauer Institute for Experimental Cellular Therapy University Hospital Essen, Germany Teaching Session II: Epitope Matching in Transplantation: Cross-linking the

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION doi:10.1038/nature12783 Bone marrow transplantation experiments While we confirmed that CD45+ bone marrow derived cells contributed to the dermis during normal homeostasis and wound healing (Fig. E9d,

More information

Lecture 24. Autoimmunity. Origins of autoimmunity. Diseases. Immune Diseases - Chapter 16 - Allergies - Autoimmunity - Immunodeficiency

Lecture 24. Autoimmunity. Origins of autoimmunity. Diseases. Immune Diseases - Chapter 16 - Allergies - Autoimmunity - Immunodeficiency Lecture 24 Immune Diseases - Chapter 16 - Allergies - Autoimmunity - Immunodeficiency Disease Diagnostics - Chapter 17 - Sample Collections - Phenotypic Method - Genotypic Method - Immunological Method

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION doi:10.1038/nature10772 Supplementary Figures: Supplementary Figure 1. Location of CNS1 within of the Foxp3 locus highlighting CNS1 and indicating transcription factor binding motifs downstream of TCR,

More information

Exam 3 4/25/07. Total of 7 questions, 100 points.

Exam 3 4/25/07. Total of 7 questions, 100 points. Exam 3 4/25/07 BISC 4A P. Sengupta Total of 7 questions, 100 points. QUESTION 1. Circle the correct answer. Total of 40 points 4 points each. 1. Which of the following is typically attacked by the antibody-mediated

More information

Investigations in Immune Suppression for Monoclonal Antibody Therapeutics

Investigations in Immune Suppression for Monoclonal Antibody Therapeutics Investigations in Immune Suppression for Monoclonal Antibody Therapeutics Vibha Jawa Principal Scientist AAPS NBC Meeting, May 2016 Clinical Immunology, Medical Sciences, Amgen Background Therapeutic proteins

More information

(Received for publication 28 August 1969)

(Received for publication 28 August 1969) SYNERGY AMONG LYMPHOID CELLS MEDIATING THE GRAFT-VERSUS-HOST RESPONSE 1I. SYNERGY IN GRAFT-VERSus-HosT REACTIONS PRODUCED BY BALB/C LYMPHOID CELLS OF DIFFERING ANATOMIC ORIGIN BY HARVEY CANTOR, M.D., AND

More information

Antibody and Immunological Memory Responses. Rolf Zinkernagel University of Zurich, Switzerland

Antibody and Immunological Memory Responses. Rolf Zinkernagel University of Zurich, Switzerland Anti-Viral Antibody and Immunological Memory Responses Rolf Zinkernagel University of Zurich, Switzerland B cells react: Polymers (Polymeric selfantigens: collagen, DNA etc.) Monomers + LPS (CpG) 2 lymphoid

More information

HLA-driven Optimization of an HIV Vaccine Immunogen Using Epitomes

HLA-driven Optimization of an HIV Vaccine Immunogen Using Epitomes HLA-driven Optimization of an HIV Vaccine Immunogen Using Epitomes N. Jojic, V. Jojic, C. Kadie, C. Meek, and D. Heckerman Microsoft Research M. John, C. Moore, and S. Mallal Royal Perth Hospital and Murdoch

More information

Immunology 2011 Lecture 9 Immunoglobulin Biosynthesis 3 October

Immunology 2011 Lecture 9 Immunoglobulin Biosynthesis 3 October Immunology 2011 Lecture 9 Immunoglobulin Biosynthesis 3 October APC Antigen processing (dendritic cells, MΦ et al.) Antigen "presentation" Ag/Ab complexes Antigenspecific triggering B T ANTIGEN Proliferation

More information

University of Alberta. Defining the Barrier of Split Tolerance in Allogeneic Mixed Chimerism

University of Alberta. Defining the Barrier of Split Tolerance in Allogeneic Mixed Chimerism University of Alberta Defining the Barrier of Split Tolerance in Allogeneic Mixed Chimerism by David Peter Al-Adra A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment

More information

Immune System. Branden & Tooze, Chapter 15 Protects complex multicellular organisms from pathogens, e.g. virus, bacteria, yeast, parasites, worms, etc

Immune System. Branden & Tooze, Chapter 15 Protects complex multicellular organisms from pathogens, e.g. virus, bacteria, yeast, parasites, worms, etc Immune System Branden & Tooze, Chapter 15 Protects complex multicellular organisms from pathogens, e.g. virus, bacteria, yeast, parasites, worms, etc Innate immunity first line of defense past physical

More information

Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology

Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing

More information

1. Immunization. What is Immunization? 12/9/2016. Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology

1. Immunization. What is Immunization? 12/9/2016. Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing

More information

Immunogenicity Prediction Where are we?

Immunogenicity Prediction Where are we? Pharma&Biotech Immunogenicity Prediction Where are we? European Immunogenicity Platform, 24th February 2016 Immunogenicity of Biopharmaceuticals Potential causes 2 Pre-clinical Immunogenicity Prediction

More information

1 R01 AI VMD HALFORD, W

1 R01 AI VMD HALFORD, W 1 R01 AI104935-01 2 VMD 1R01AI104935-01 ILLIAM CRITIQUE 1: Significance: 5 Investigator(s): 2 Innovation: 5 Approach: 8 Environment: 2 Overall Impact: This application proposes to develop a recombinant

More information

Biological immune systems

Biological immune systems Immune Systems 1 Introduction 2 Biological immune systems Living organism must protect themselves from the attempt of other organisms to exploit their resources Some would-be exploiter (pathogen) is much

More information

Supplemental Information

Supplemental Information Supplemental Information DLA-matched bone marrow transplantation reverses the immunodeficiency of SCID dogs. Bone marrow transplantation studies were initiated with the goal of reversing the immunodeficiency

More information

Antibodies (Immunoglobulins)

Antibodies (Immunoglobulins) Antibodies (Immunoglobulins) The immune system plays a major role in the body s defense mechanisms against pathogens and other foreign bodies. It protects organisms from infection with a layered defense

More information

Highlight Product : QuickSwitch Custom Tetramer Kits. Featured Product : PCSK9 ELISA Kit & PCSK9-LDLR in vitro Binding Assay Kit

Highlight Product : QuickSwitch Custom Tetramer Kits. Featured Product : PCSK9 ELISA Kit & PCSK9-LDLR in vitro Binding Assay Kit vol.1 Sep. 2017 Highlight Product : QuickSwitch Custom Tetramer Kits Featured Product : PCSK9 ELISA Kit & PCSK9-LDLR in vitro Binding Assay Kit Attended The 8th International Symposium on Autophagy Hi,

More information

Implementation of Artificial Immune System Algorithms

Implementation of Artificial Immune System Algorithms Implementation of Artificial Immune System Algorithms K. Sri Lakshmi Associate Professor, Department of CSE Abstract An artificial immune system (AIS) that is distributed, robust, dynamic, diverse and

More information

BNG 331 Cell-Tissue Material Interactions. Wound Healing I

BNG 331 Cell-Tissue Material Interactions. Wound Healing I BNG 331 Cell-Tissue Material Interactions Wound Healing I Course update LBL 4 Friday; paper posted Need a volunteer to switch groups! Much better job on LBL 3 figure summaries BNG spring seminar 3 this

More information

LAMPIRE Hybridoma Project Initiation Form

LAMPIRE Hybridoma Project Initiation Form 1. General Information Company / Institution: Investigator Name: Contact Name: Phone: Fax: 2. Billing / Shipping Information Accounts Payable contact: Company: Dept./Bldg./Room#: Address: Project Name

More information

Artificial Immune Systems

Artificial Immune Systems Artificial Immune Systems Dr. Mario Pavone Department of Mathematics & Computer Science University of Catania mpavone@dmi.unict.it http://www.dmi.unict.it/mpavone/ Biological Immune System (1/4) Immunology

More information

Metodi e tecniche di ottimizzazione innovative per applicazioni elettromagnetiche

Metodi e tecniche di ottimizzazione innovative per applicazioni elettromagnetiche Metodi e tecniche di ottimizzazione innovative per applicazioni elettromagnetiche Algoritmi stocastici Parte 3 Artificial Immune Systems M. Repetto Dipartimento Ingegneria Elettrica Industriale - Politecnico

More information

CONTRACTING ORGANIZATION: Albert Einstein College of Medicine Bronx, NY 10461

CONTRACTING ORGANIZATION: Albert Einstein College of Medicine Bronx, NY 10461 AD Award Number: W81XWH-08-1-0011 TITLE: Defining B. Anthracis Protective Antigen Antigenic Domains PRINCIPAL INVESTIGATOR: Arturo Casadevall, M.D., Ph.D. CONTRACTING ORGANIZATION: Albert Einstein College

More information

Outline. o Immunogenicity of therapeutic protein aggregates. o Clinical evidence. o Models to study the immunogenicity of aggregates

Outline. o Immunogenicity of therapeutic protein aggregates. o Clinical evidence. o Models to study the immunogenicity of aggregates Immunogenicity of Therapeutic Protein Aggregates Ehab Moussa 11-14-2016 Outline o Immunogenicity of therapeutic protein aggregates o Clinical evidence o Models to study the immunogenicity of aggregates

More information

Mastering Immunity. Nikolai Schwabe, CEO. Tools & Technologies for Managing Immunogenicity Risk - where does the rubber meet the road?

Mastering Immunity. Nikolai Schwabe, CEO. Tools & Technologies for Managing Immunogenicity Risk - where does the rubber meet the road? Mastering Immunity Tools & Technologies for Managing Immunogenicity Risk - where does the rubber meet the road? Nikolai Schwabe, CEO About ProImmune HQ in Oxford UK since 2000, US office since 2004 Specialist

More information

Chapter 3 The Immune System

Chapter 3 The Immune System Chapter 3 The Immune System Why is the Immune System Important? Why is the Immune System Relevant to HIV? T Lymphocyte Infected by HIV Brief History of Immunology Immunity- Observation reported in 430

More information

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects

More information

MCB 4211, Fall 2018, Practice Exam 1 Last, First name Student ID # Seat No. ***NOTE: Exam will have 40 multiple choice questions.

MCB 4211, Fall 2018, Practice Exam 1 Last, First name Student ID # Seat No. ***NOTE: Exam will have 40 multiple choice questions. MCB 4211, Fall 2018, Practice Exam 1 Last, First name Student ID # Seat No. ***NOTE: Exam 1 2018 will have 40 multiple choice questions. READ ALL THE CHOICES AND SELECT THE BEST 1. Which of the following

More information

a. Hypoxanthine was present in the media. MCB 4211, Fall 2018, Practice Exam 1 Last, First name Student ID # Seat No.

a. Hypoxanthine was present in the media. MCB 4211, Fall 2018, Practice Exam 1 Last, First name Student ID # Seat No. MCB 4211, Fall 2018, Practice Exam 1 Last, First name Student ID # Seat No. ***NOTE: Exam 1 2018 will have 40 multiple choice questions. READ ALL THE CHOICES AND SELECT THE BEST 1. Which of the following

More information

New Methods of Expanding T Cells. Mark E. Dudley, Ph.D. Surgery Branch National Cancer Institute

New Methods of Expanding T Cells. Mark E. Dudley, Ph.D. Surgery Branch National Cancer Institute New Methods of Expanding T Cells Mark E. Dudley, Ph.D. Surgery Branch National Cancer Institute Autologous T Cell and Gene Therapies Service Product New tools for T cell expansion Early clinical trials

More information

Nature Immunology: doi: /ni Supplementary Figure 1. Time course of OT-II T reg cell development in thymic slices.

Nature Immunology: doi: /ni Supplementary Figure 1. Time course of OT-II T reg cell development in thymic slices. Supplementary Figure 1 Time course of OT-II T reg cell development in thymic slices. Time course of T reg cell development following addition of OT-II TCR transgenic Rag2 -/- mice (OT-II) thymocytes to

More information

REGISTRATION DOCUMENT FOR RECOMBINANT DNA RESEARCH

REGISTRATION DOCUMENT FOR RECOMBINANT DNA RESEARCH EHRS Date Received: Reg. Doc. No.: REGISTRATION DOCUMENT FOR RECOMBINANT DNA RESEARCH Principal Investigator: Penn ID#: Position Title: School: Department: Mailing Address: Mail Code: Telephone: FAX: E-mail:

More information

Anja Holm Danish Medicines Agency. Genetic vaccines Oslo, 2008

Anja Holm Danish Medicines Agency. Genetic vaccines Oslo, 2008 Anja Holm Danish Medicines Agency Genetic vaccines Oslo, 2008 Ministry of Food, Agriculture and Fisheries Danish Veterinary Institute Technical review & discussion of safety issues Author: Anja Holm. Anja

More information

THE BEHAVIOR OF SKIN GRAFTS INCOMPATIBLE WITH RESPECT TO SKIN ALLOANTIGENS ON MICE RENDERED TOLERANT AT BIRTH WITH LYMPHOID CELLS*

THE BEHAVIOR OF SKIN GRAFTS INCOMPATIBLE WITH RESPECT TO SKIN ALLOANTIGENS ON MICE RENDERED TOLERANT AT BIRTH WITH LYMPHOID CELLS* Published Online: 1 June, 1976 Supp Info: http://doi.org/10.1084/jem.143.6.1317 Downloaded from jem.rupress.org on July 3, 2018 THE BEHAVIOR OF SKIN GRAFTS INCOMPATIBLE WITH RESPECT TO SKIN ALLOANTIGENS

More information

Product Data Sheet - TRUEMAB

Product Data Sheet - TRUEMAB 888.267.4436 techsupport@origene.com www.origene.com Name:CD34 mouse monoclonal antibody, clone OTI12F2 (formerly 12F2) Product Data Sheet - TRUEMAB Catalog: TA808864 Components: CD34 mouse monoclonal

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Veterinary Use CVMP/IWP/07/98-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES

More information

ANTIBODY IMMUNOGENICITY

ANTIBODY IMMUNOGENICITY ANTIBODY IMMUNOGENICITY Tolerance Classical Immunity To aggegated Antibody Chiller and Weigle, PNAS, 65:551, 1970; Benjamin and Waldmann, et al, J Exp Med, 163:1539, 1986) THE IMMUNOGENICITY PROBLEM WITH

More information

Chapter 3. Clonal selection

Chapter 3. Clonal selection Chapter 3. Clonal selection I have called this principle, by which each slight variation, if useful, is preserved, by the term of Natural Selection -Charles Darwin, On the Origin of Species, 1859 4 The

More information

Antibody Structure. Antibodies

Antibody Structure. Antibodies Antibodies Secreted by B lymphocytes Great diversity and specificity: >10 9 different antibodies; can distinguish between very similar molecules Tag particles for clearance/destruction Protect against

More information

Antibody Structure supports Function

Antibody Structure supports Function Antibodies Secreted by B lymphocytes Great diversity and specificity: >10 9 different antibodies; can distinguish between very similar molecules Tag particles for clearance/destruction Protect against

More information

Proposed Mechanisms for Aggregate Induced Immunogenicity

Proposed Mechanisms for Aggregate Induced Immunogenicity Proposed Mechanisms for Aggregate Induced Immunogenicity Science 262, 1448-1451 1 rganization: high low absent Antibody response +++ + - Induction of auto-antibodies +++ - - Recombinant Protein Therapy

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION doi: 1.138/nature875 a promoter firefly luciferase CNS b Supplementary Figure 1. Dual luciferase assays on enhancer activity of CNS1, 2, and 3. a. promoter sequence was inserted upstream of firefly luciferase

More information

Supplementary material

Supplementary material Supplementary material Tracking mesenchymal stem cell contributions to regeneration in an immunocompetent cartilage regeneration model Daniela Zwolanek, María Satué, Verena Proell, Josè R. Godoy, Kathrin

More information

TGFβ/TGFβR3 Signaling Pathways in Autoimmune Disease

TGFβ/TGFβR3 Signaling Pathways in Autoimmune Disease Holifield 1 TGFβ/TGFβR3 Signaling Pathways in Autoimmune Disease Reggie Holifield Faculty mentor: Dr. Christine Sestero The University of Montevallo Dept. of Biology, Chemistry, and Mathematics Abstract

More information

REGISTRATION DOCUMENT FOR RECOMBINANT & SYNTHETIC DNA RESEARCH

REGISTRATION DOCUMENT FOR RECOMBINANT & SYNTHETIC DNA RESEARCH IBC Date Received: Reg. Doc. No.: REGISTRATION DOCUMENT FOR RECOMBINANT & SYNTHETIC DNA RESEARCH Principal Investigator: --------------------------------------- Position Title: -------------- Department:

More information

Immunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals

Immunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals Immunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals Daniel Kramer/Kathleen Beach Need for public-private collaboration 1 All biopharmaceuticals are

More information

ADCC and HVEM: Lessons from an HSV-2 ΔgD vaccine. Clare Burn Laboratory of Betsy Herold and Laboratory of William R. Jacobs, Jr.

ADCC and HVEM: Lessons from an HSV-2 ΔgD vaccine. Clare Burn Laboratory of Betsy Herold and Laboratory of William R. Jacobs, Jr. ADCC and HVEM: Lessons from an HSV-2 ΔgD vaccine Clare Burn Laboratory of Betsy Herold and Laboratory of William R. Jacobs, Jr. 1 Herpes Simplex Viruses Predominantly infect epithelial cells; establish

More information

Cytotoxic T-Lymphocyte Epitope Immunodominance in the Control of Choroid Plexus Tumors in Simian Virus 40 Large T Antigen Transgenic Mice

Cytotoxic T-Lymphocyte Epitope Immunodominance in the Control of Choroid Plexus Tumors in Simian Virus 40 Large T Antigen Transgenic Mice JOURNAL OF VIROLOGY, July 1999, p. 5981 5993 Vol. 73, No. 7 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Cytotoxic T-Lymphocyte Epitope Immunodominance

More information

BEH.462/3.962J Molecular Principles of Biomaterials Spring 2003

BEH.462/3.962J Molecular Principles of Biomaterials Spring 2003 Lecture 17: Drug targeting Last time: Today: Intracellular drug delivery Drug targeting Reading: T.J. Wickham, Ligand-directed targeting of genes to the site of disease, Nat. Med. 9(1) 135-139 (2003) Drug

More information

Viruses and Bacteria Notes

Viruses and Bacteria Notes Viruses and Bacteria Notes A. Virus Structure: Viruses are in contrast to bacteria. Viruses are (DNA or RNA) enclosed in a coat called a. Also some viruses have a that helps them infect their host. These

More information

Nature Biotechnology: doi: /nbt.4086

Nature Biotechnology: doi: /nbt.4086 Ag (-) anti-cd3 p815 p815-hcd2 Ag (-) anti-cd3 p815 p815-hcd2 Ag (-) anti-cd3 p815 p815-hcd2 Ag (-) anti-cd3 p815 p815-hcd2 Ag (-) anti-cd3 p815 p815-hcd2 Ag (-) anti-cd3 p815 p815-hcd2 Ag (-) anti-cd3

More information

Who pairs with whom? High-throughput sequencing of the human paired heavy and light chain repertoire

Who pairs with whom? High-throughput sequencing of the human paired heavy and light chain repertoire Who pairs with whom? High-throughput sequencing of the human paired heavy and light chain repertoire Technical Journal Club September 15 th Christina Müller Background - antibody repertoire is the sum

More information

Some Scaling Principles for the Immune System

Some Scaling Principles for the Immune System Immunology and Cell Biology (2004) 82, 27 3 doi:0.046/j.088-964.2004.0229.x Theoretical Article Some Scaling Principles for the Immune System F R E D E R I K W W I E G E L a n d A L A N S P E R E L S O

More information

Nature Immunology: doi: /ni Supplementary Figure 1. Data-processing pipeline.

Nature Immunology: doi: /ni Supplementary Figure 1. Data-processing pipeline. Supplementary Figure 1 Data-processing pipeline. Steps for processing data from multiple sorted B cell populations derived from a single individual at a single time point are shown. Parameters used are

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our

More information

Platelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD

Platelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD Platelet Refractoriness: The Basics Martin H. Bluth, MD, PhD Complete Toxicology Laboratories, LLC Objectives Define platelet refractoriness and associated conditions that may cause platelet refractoriness.

More information

B cells Harry W Schroeder Jr MD PhD

B cells Harry W Schroeder Jr MD PhD B cells Harry W Schroeder Jr MD PhD Division of Clinical Immunology and Rheumatology Departments of Medicine, Microbiology, and Genetics University of Alabama at Birmingham Director, UAB Program in Immunology

More information

ANTIBODY REPERTOIRES AND PATHOGEN RECOGNITION: THE ROLE OF GERMLINE DIVERSITY AND SOMATIC HYPERMUTATION.

ANTIBODY REPERTOIRES AND PATHOGEN RECOGNITION: THE ROLE OF GERMLINE DIVERSITY AND SOMATIC HYPERMUTATION. Mihaela L. Oprea Candidate Department of Computer Science Department This dissertation is approved, and it is acceptable in quality and form for publication on microfilm: Approved by the Dissertation Committee:,

More information

Introduction to Cell- Biomaterial Engineering!

Introduction to Cell- Biomaterial Engineering! Introduction to Cell- Biomaterial Engineering! Module 3, Lecture 1! 20.109 Spring 2010! Topics for Lecture 1!! Introduction to tissue engineerin! motivation"! basic principles + examples"! Introduction

More information

INDUCTION OF B CELL TOLERANCE IN VITRO TO 2,4-DINITRO- PHENYL COUPLED TO A COPOLYMER OF D-GLUTAMIC ACID AND I)-LYSINE (DNP-D-GL)*

INDUCTION OF B CELL TOLERANCE IN VITRO TO 2,4-DINITRO- PHENYL COUPLED TO A COPOLYMER OF D-GLUTAMIC ACID AND I)-LYSINE (DNP-D-GL)* INDUCTION OF B CELL TOLERANCE IN VITRO TO 2,4-DINITRO- PHENYL COUPLED TO A COPOLYMER OF D-GLUTAMIC ACID AND I)-LYSINE (DNP-D-GL)* BY G. J. V. NOSSAL, BEVERLEY L. PIKE, AND DAVID H. KATZ (From The Walter

More information

Case study: Specification of CD4+ T cell epitopes of human FVIII. Birgit Reipert Director Immunology TA Hemophilia/Hematology Baxter BioScience

Case study: Specification of CD4+ T cell epitopes of human FVIII. Birgit Reipert Director Immunology TA Hemophilia/Hematology Baxter BioScience Case study: Specification of CD4+ T cell epitopes of human FVIII Birgit Reipert Director Immunology TA Hemophilia/Hematology Baxter BioScience Mastering Immunogenicity, Boston MA, September 12-13 2011

More information

The presenter declare no conflict of interest This work was partly supported by Selecta Bioscience

The presenter declare no conflict of interest This work was partly supported by Selecta Bioscience Modulation of AAV vector dosing and avoidance of capsid immune responses via repeated co-administration of vector with rapamycin tolerogenic nanoparticles Amine Meliani The presenter declare no conflict

More information

The Immune System and Microgravity. Overview in Humans. Innate Immunity

The Immune System and Microgravity. Overview in Humans. Innate Immunity The Immune System and Microgravity Dr. Patricia C. Hunt DO, MHA, CHCQM Overview in Humans There are two types of immune response: innate immunity First line of defense when a microbe enters the body. Rapid

More information

Topic (7): Antibodies and Antigens

Topic (7): Antibodies and Antigens Topic (7): Antibodies and Antigens INTRODUCTION Antibodies (Abs) are one of the three classes of molecules able to differentiate between antigens [Ags] (the other two are T-cell receptor [TCR] and major

More information

Biomarkers, Early Prediction of Vaccine Efficacy and Safety

Biomarkers, Early Prediction of Vaccine Efficacy and Safety Biomarkers, Early Prediction of Vaccine Efficacy and Safety Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine Research Institute Lausanne

More information

Measurement of peritoneal macrophage apoptosis by Celigo plate imaging cytometer

Measurement of peritoneal macrophage apoptosis by Celigo plate imaging cytometer SUPPLEMENTAL METHODS Measurement of peritoneal macrophage apoptosis by Celigo plate imaging cytometer For Celigo experiments, 0.1 ml containing 5 x 10 4 cells was seeded into 96 well plates for 30 min

More information